The FDA has officially cleared the Dexcom G5 continuous glucose monitor to inform treatment decisions -- without the use of a fingerstick glucometer, other than for calibration. The G5 has been ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

For the first time, the US Food and Drug Administration has approved the use of a continuous glucose monitoring (CGM) system to replace finger-stick testing for determining insulin doses. The decision ...

This approval marks the Company’s fifth new insulin pump launch in only 5 years and the second featuring Dexcom technology. It is the only available pump that conveniently displays a user’s insulin ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, Dexcom, Inc.

March 24--Shares of DexCom gained more than 8 percent Friday after Medicare issued a favorable ruling for reimbursing use of continuous glucose monitors, made by the San Diego-based company. DexCom ...

Dexcom is in the middle of a direct-to-consumer advertising campaign for its G5 Mobile CGM System. Is this DTC strategy paying off? In coordination with a new product launch, Dexcom, Inc., a major ...

Dexcom, Inc., a leader in continuous glucose monitoring (CGM) for patients with diabetes, today announced the availability of enhanced data sharing features for physician and patient users of the ...

Dexcom has announced a massive and serious continuous glucose monitors recall, involving more than 260,000 devices with alarms that may fail to sound. Rather than asking customers to return the ...

Traders raked in $4 billion in profit from their short positions in Tesla shares on Thursday after a public feud between President Donald Trump and CEO Elon Musk drove the biggest single-day drop in ...

Leerink Partners analyst Mike Kratky maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $161.00. Mike Kratky has given his Buy rating due to a combination ...